



Agerafenib (CEP-32496;RXDX105)

Catalog No: tcsc1115

Available Sizes
Size: 5mg
Size: 10mg
Size: 50mg
Size: 100mg
Specifications Specifications
CAS No: 1188910-76-0
Formula: $C_{24}^{H}_{22}^{F}_{3}^{N}_{5}^{O}_{5}$
Pathway: MAPK/ERK Pathway
Target: Raf
Purity / Grade: >98%
Solubility: 10 mM in DMSO
Alternative Names: CEP-32496; RXDX-105
Observed Molecular Weight: 517.46





Product Description

Agerafenib (CEP-32496; RXDX-105) is a highly potent and orally efficacious inhibitor of $\mathbf{BRAF}^{\mathbf{V600E}}$ with a $\mathbf{K_d}$ of 14 nM.

IC50 & Target: Kd: 14 nM (BRAF V600E), 36 nM (wt BRAF),39 nM (CRAF), 2 nM (c-Kit), 2 nM (Ret), 2 nM (LCK), 3 nM (Abl-1), 8 nM (VEGFR-2), 9 nM (CSF-1R), 14 nM (EPHA2), 22 nM (EGFR), 513 nM (c-Met), 4700 nM (JAK-2), 7100 nM (MEK-1), 8300 nM (MEK-2) $^{[1]}$

In Vitro: Agerafenib (CEP-32496) exhibits high potency against several BRAF^{V600E}-dependent cell lines and selective cytotoxicity for tumor cell lines expressing mutant BRAF^{V600E} versus those containing wild-type BRAF. Agerafenib exhibits potent binding (BRAF V600E $\rm K_d$ =14 nM) and cellular activity (pMEK $\rm IC_{50}$ =82 nM and A375 proliferation $\rm IC_{50}$ =78 nM), with activity in the proliferation assay. Agerafenib also exhibits a favorable CYP450 inhibition profile, with measured $\rm IC_{50}$ values greater than 10 $\rm \mu M$ versus the CYP1A2, CYP2C9, CYP2D6, and CYP3A4 isoforms and an $\rm IC_{50}$ =3.4 $\rm \mu M$ versus CYP2C19^[1].

In Vivo: Oral administration of Agerafenib (CEP-32496) to Colo-205 tumor xenograft-bearing mice results in significant inhibition of pMEK in tumor cell lysates. For instance, a single 30 mg/kg (po) dose of Agerafenib leads to a 50 and 75% inhibition of normalized pMEK in tumor lysates at the 2 and 6 h postdose time point, respectively (p[1].

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!